Skip to main content

Understanding Risk Statements Within Drug Injury Advertising: An Abstract

  • Conference paper
  • First Online:
Marketing Opportunities and Challenges in a Changing Global Marketplace (AMSAC 2019)

Abstract

Televised drug injury ads, sponsored by law firms or legal referral networks, identify injured consumers for lawsuits against pharmaceutical companies. They generally consist of warnings to the public about dangerous side effects associated with a particular drug and conclude with a phone number for consumers to call if they have experienced the side effect. Because the drugs discussed in the ads remain available on the market, drug injury ads have the potential to influence the prospective medical decisions of viewers. This research considers how differences in the content of drug injury ads affect consumer perceptions and intentions toward the featured medications. We report the results of two experiments using modified versions of actual drug injury ads.

The first study tested which elements of drug injury ads most strongly affect consumer evaluations and intentions. The results of Study 1 suggested that ads which begin with warnings reduce the likelihood of correct sponsor identification and reduce the likelihood that participants will (re)fill a prescription. Further, elements which made it more obvious that the ad was sponsored by a lawyer increased the likelihood of correct sponsor identification.

In Study 2 we manipulated Sponsor Identification (obvious sponsor vs. non-obvious sponsor) and the vividness of the Risk Statement (more-vivid risk vs. less-vivid risk) in a between-subject design. Our results indicate that when the persuasive intent of the advertisement is less clear (e.g., the sponsor is less obvious), vivid Risk Statements seem especially impactful and can affect intentions toward discontinuing the medications featured in the ads.

An effective remedy for addressing the misleading character of some ads may be to require attorneys to prominently disclose the sponsor, preferably at the start of the ad. Prominent early disclosures about advertising sponsorship would be especially important where the side effects are severe, when the ad includes vivid graphic imagery of medical harms (e.g., an image of a person clutching their chest, or lying in a hospital bed), or where the ad contains strong cautionary language (“warning”).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jesse King .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2020 The Academy of Marketing Science

About this paper

Check for updates. Verify currency and authenticity via CrossMark

Cite this paper

King, J., Tippett, E. (2020). Understanding Risk Statements Within Drug Injury Advertising: An Abstract. In: Wu, S., Pantoja, F., Krey, N. (eds) Marketing Opportunities and Challenges in a Changing Global Marketplace. AMSAC 2019. Developments in Marketing Science: Proceedings of the Academy of Marketing Science. Springer, Cham. https://doi.org/10.1007/978-3-030-39165-2_26

Download citation

Publish with us

Policies and ethics